We get ahead of disease together by preventing and treating it with innovation in vaccines and specialty medicines. Our R&D approach combines our scientific focus on the immune system - with the use of advanced technologies.
We are working to deliver a new generation of differentiated, needed vaccines and medicines in four core therapeutic areas where we have the strongest expertise, and where significant patient need remains:respiratory, immunology and inflammation; oncology, HIV; and infectious diseases.
Technology powers all aspects of our R&D. We use human genetics and functional genomics, along with artificial intelligence and machine learning (AI/ML), to deeply understand the patient, human biology, and disease mechanisms. This is leading to real breakthroughs for tackling a range of conditions, such as liver disease, or transforming HIV treatment and prevention.
We believe the powerful combination of science and technology holds the key to fundamentally transforming medical discovery for the better, making the R&D process more dynamic, improving success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new medicines and vaccines to address the root cause of disease.
Tony Wood
Chief Scientific Officer
Our worldwide R&D network of sites includes strategic global hubs in US, UK, Belgium and key expert facilities in Italy and Spain
We are investing in innovation in the US
Branford, Connecticut
Branford, Connecticut
Branford is the sole location for ViiV Healthcare R&D and Clinical Development. Here, we work on discovery and synthesis of chemical compounds, discovery of targets for drug development, compound screening in biological assays, antibody development and characterization, assay development, clinical sample testing.
Durham, North Carolina
Durham, North Carolina
ViiV recently moved into dedicated laboratory and office space in Durham, North Carolina’s newly created Innovation District. The team will consist of 10-20 lab-based individuals, and their work is a collaborative effort with the Branford site.
Cambridge Park Drive - Cambridge, Massachusetts
Cambridge Park Drive - Cambridge, Massachusetts
Our Cambridge Park Drive facility is a bio research laboratory. Its mission is ELT Chemistry and Biology, Immunology, and Immuno-oncology. To support these activities there is a staff of 76, including 14 scientists working in bio safety level 2 containment labs.
Technology Square - Cambridge, Massachusetts
Technology Square - Cambridge, Massachusetts
Our Technology Square R&D facility is a bio research laboratory adjacent to MIT. The facilities’ mission is oncology, human genetics, AI/ML, functional genomic, and recombinant DNA research. To support these activities there is a staff of 36, including 15 scientists working in bio safety level 2 containment facilities and in a vivarium.
Rockville, Maryland
Rockville, Maryland
Our Rockville Center for Vaccines Research (RCVR) is home of the GSK's Vaccine headquarters for the America's region. Approximately 50% of the colleagues based here are focused on Vaccines R&D efforts, with the remainder of the employees focused on support functions such as Regulatory, Legal, and Facilities.
Upper Merion, Pennsylvania
Upper Merion, Pennsylvania
Our Upper Merion campus is the US Pharma Research and Development Biopharm Center of Excellence. This facility is shared with Global Supply Chain who operate biopharmaceutical manufacturing space and manufacturing support space.
Upper Providence, Pennsylvania
Upper Providence, Pennsylvania
Our Upper Providence R&D Hub is the heart of innovation, discovering and developing differentiated, high-quality and needed medicines that are bringing transformational benefit to patients. It is home to 3,400 employees, 40% of our global R&D workforce.
Binney Street, Cambridge, Massachusetts
Binney Street, Cambridge, Massachusetts
Home to more than 200 colleagues focused on the use of MAPS technology. The site has been designed to offer a holistic and agile approach with all vaccine development in one place: from discovery to manufacturing.
We believe the bigger the challenge the bigger the need for collaboration. We know that by working we others we can achieve more for patients than alone.
We innovate with others, because no single scientist, nor any one technology can keep us all ahead of disease. Strategic partnerships are critical to opening up new avenues of discovery and advancing the development of new potential medicines and vaccines. GSK has more than 100 active alliances in biotech and academia.
As a global biopharma leader, we invest heavily in our industry-leading pipeline of potential specialty medicines and vaccines that help us to get ahead of disease together.
R&D is central to our purpose to get ahead of disease together. By combining the science of the immune system with cutting-edge technology, we can discover and develop new medicines and vaccines that will transform people’s lives.
Assets
71
Medicines and vaccines in development in 2024
Phase I
9
Phase I programmes started in 2024
Collaboration with US universities UCSF/UC Berkeley
The Laboratory for Genomics Research to foster innovative technologies
The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, respiratory/immunology, and oncology. We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
Explore more about our therapeutic areas on our global website, below.
